News

September 2016 Newsletter

As I write this, we are in the midst of a successful Olympic games held in Rio de Janeiro, and looking forward to the IASLC's 7th Latin American Conference on Lung Cancer (LALCA).

DENVER – The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.

DENVER – Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis.

DENVER – Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Patients receiving tyrosine kinase inhibitors (TKIs) targeting EGFR mutations had a longer overall survival (OS) than those who did not receive TKIs, demonstrating the effectiveness of TKIs for LM therapy.

August 2016 Newsletter

Every day I spend in my lung cancer clinic I see happy and sad stories.

DENVER – After nearly 30 years of IASLC membership and a career in groundbreaking research, the IASLC proudly recognizes Dr. Giorgio V. Scagliotti, President-Elect of IASLC, Professor and Chair of Medical Oncology at the University of Turin and San Luigi Hospital in Italy, who recently received the 2016 Addario Lectureship Award.

Pages